Motrin viral suffers digital slings and arrows

Share this article:
J&J's Motrin viral ad
J&J's Motrin viral ad
In a reminder that the new media world is not without its perils, Johnson & Johnson is backpedaling from a Motrin campaign about slings aimed at moms that drew arrows from the Stroller Mafia.

Viral ads online and print ads in magazines appealed to achy moms sore from carrying their kids in slings. But the tongue-in-cheek campaign sparked a storm of spoof response videos and cranky ripostes on Twitter.

Kathy Widmer, VP marketing for McNeil Consumer Healthcare, wrote on the company's JNJ BTW blog that the Motrin maker was taking the ads down, while noting that some print ads were already on newsstands.

“This weekend, a lot was said about Motrin on Twitter and in the blogosphere,” said Widmer. “Unfortunately, it was not the kind of conversation that we here at McNeil had hoped to be at the center of.”

Widmer noted that much of the ire centered on the ads' snarky take on the practice of “baby wearing.” The viral ad's narrator says: “Supposedly it's a real bonding experience. They say that babies carried close to the body tend to cry less than others. But what about me?”

“It was meant to engender sympathy and appreciation for all that parents do for their kids, but did so through an attempt at humor that missed the mark and many moms found offensive.”

“One bright spot is that we have learned through this process—in particular, the importance of paying close attention to the conversations that are taking place online.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...